CLDI Calidi Biotherapeutics, Inc.
Listings ·
The notice, received September 21, 2026, says Calidi does not meet the exchange's stockholders' equity standard. The company must submit a compliance plan by October 21, 2026.
Calidi, director and ex-CEO Allan Camaisa and ex-officer Ms. Pizarro are defendants in San Diego employment suits. Investor Yian Zeng's federal case against Calidi had a summary judgment hearing set for Aug 24, 2026.
The split became effective July 30, 2026, and the common stock began trading split-adjusted on July 31 under the existing CLDI symbol.
The company signed a 44-month lease for Suite 120 at 5580 Morehouse Drive and agreed to terminate its existing lease, effective September 30, 2026.
Dr. Corsee Sanders, a former Genentech/Roche and Celgene executive, joined the board as an independent director effective June 17, 2026.
Calidi Biotherapeutics replaced a May 6 warrant for up to 17,391,304 shares at $0.23 with one that cannot be exercised until stockholders approve it. The minimum vesting amount doubles to $1,000,000 and the vesting deadline moves to September 30, 2026.
Calidi reported a first quarter net loss of $4.4 million, a $1.0 million cut in general and administrative expenses and a CLD-401 IND goal of year end 2026.
Nova Cell pays by cancelling a net $1,214,864 of debt Calidi owed it, plus $4,785,136 of deferred, contingent consideration. Nova Cell is no longer a subsidiary, and the company expects $0.5 million a year in expense cuts.
The offering combines common stock units and pre-funded warrant units, each with a Series I warrant exercisable at $2.00 for five years.
The notice, dated October 28, 2024, covers the company's redeemable warrants with a $115.00 exercise price, not its common stock.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $9.7 million | $8.9 million |
| Net income (loss) | -$19.9 million | -$22.1 million |
| Cash from operations | -$21.3 million | -$19.7 million |
| Cash and equivalents | $5.8 million | $9.6 million |
Our latest story on this, dated Jul 27, 2026: "Calidi Biotherapeutics effects 1-for-16 reverse stock split". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 15, 2025: "Calidi Biotherapeutics prices $6 million public offering of units at $2.00". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 25, 2026: "Calidi Biotherapeutics receives NYSE American equity deficiency notice". The story links the filing or release it is based on. Read the story.
Calidi Biotherapeutics, Inc. trades under the ticker CLDI on AMEX.
Calidi Biotherapeutics, Inc. is listed on AMEX.
The SEC Central Index Key (CIK) for Calidi Biotherapeutics, Inc. is 1855485. Its filings are on SEC EDGAR.
2,584,184 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Calidi Biotherapeutics, Inc. under United States.
Our directory classifies Calidi Biotherapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Calidi Biotherapeutics, Inc. is US3207035078.
aibio.space lists Calidi Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Calidi Biotherapeutics, Inc. reported a net loss of $19.9 million for the fiscal year ended Dec 31, 2025, and used $21.3 million of cash in operations, per its annual report to the SEC.
$9.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
$4.3 million in cash at Jun 30, 2026, per its 10-Q.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,9.01). Source
Reported a financing. SEC Form S-1. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.02,7.01,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a financing. SEC Form S-1. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,2.02,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio